A larger diameter of the main pulmonary artery predicts poorer outcomes in pulmonary arterial hypertension (PAH) patients, a study found.
Study objectives: Prior to the availability of the oral endothelin antagonist bosentan, most patients with pulmonary arterial hypertension (PAH) were treated with continuously infused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results